Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology as a simplified analog of Epithalamin — a polypeptide fraction extracted from bovine pineal glands. That relationship matters, because the two get conflated constantly in how this compound is marketed, and the evidence quality is not the same for both.
What Is Epithalon?
Epithalon is the specific four-amino-acid sequence Khavinson's team identified as the minimal active fragment of Epithalamin. It's studied for telomerase activation, pineal/melatonin regulation, and longevity in preclinical models.
Mechanism of Action
The most specific, most-cited finding is direct: adding Epithalon to cultures of telomerase-negative human fetal fibroblasts induced expression of the telomerase catalytic subunit (hTERT), increased telomerase enzymatic activity, and was associated with telomere elongation over the culture period. A companion study from the same group found Epithalon-treated fibroblast cultures exceeded the conventional Hayflick division limit by roughly ten additional population doublings versus untreated controls.
This telomerase work is cell-culture data (human fetal fibroblasts), not a human clinical trial. It demonstrates the mechanism is real in vitro, not that taking Epithalon extends telomeres in a living person.
The Epithalon vs. Epithalamin Distinction
This is the single most important thing to get right about this compound. Khavinson's group separately ran a long-term human study — 266 elderly patients over six to eight years — testing Epithalamin (the original pineal-gland extract) and Thymalin (a related thymus extract), and reported striking results: Epithalamin alone associated with a 1.6–1.8-fold mortality reduction, combined Epithalamin+Thymalin with a 2.5-fold reduction, and annual combined treatment over six years with a 4.1-fold reduction.
Those mortality numbers are for Epithalamin, the natural pineal extract — not Epithalon, the synthetic single-peptide research compound sold by vendors. They are related substances from the same research program, not the same thing. The mortality study also was not randomized, double-blind, or placebo-controlled to Western trial standards, which is a separate limitation on top of the substance mismatch. Citing this mortality data as evidence for Epithalon specifically is a common but real error in how this compound gets marketed.
What the Broader Research Shows
- Telomerase (hTERT) induction and telomere elongation in human fibroblast cultures
- Extended replicative lifespan past the Hayflick limit in the same cell-culture model
- Stimulation of melatonin production, studied in connection with pineal gland regulation
- Lifespan-extension effects reported in rodent models
Regulatory Status
Epitalon was one of seven peptides FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed on July 23–24, 2026 for the Section 503A Bulk Drug Substances List — the same meeting that reviewed BPC-157 and TB-500 (see our BPC-157 guide for the fuller background). FDA staff recommended against all seven; the committee voted narrowly to recommend Epitalon anyway, one of six peptides the panel backed — only Emideltide was voted down.
This is a non-binding recommendation, not an approval. Formal rulemaking, if FDA pursues it, could take until 2027 or 2028. Epithalon remains not FDA-approved for any human use today.
Where to Source Epithalon for Research
For legitimate research applications, purity and accurate dosing are critical. We only list vendors who provide third-party HPLC testing and batch-specific Certificates of Analysis.
View the Epithalon product page →Frequently Asked Questions
Is Epithalon the same thing as Epithalamin?
No. Epithalamin is the original polypeptide extract from bovine pineal glands. Epithalon is a synthetic four-amino-acid analog Khavinson's group identified as its active fragment. The dramatic elderly-mortality data widely cited for this compound family is from Epithalamin trials, not Epithalon.
Has Epithalon been shown to extend telomeres in humans?
No published human trial has tested this. The telomerase-activation and telomere-elongation findings are from human fibroblast cell cultures, not living human subjects.
Is Epithalon FDA-approved?
No. A July 2026 FDA advisory committee voted to recommend adding it to the compounding-eligible substances list, over FDA staff's own objection, but that's a non-binding recommendation, not an approval. It remains not FDA-approved for any human use.
References
1. Khavinson VK, Bondarev IE, Butyugov AA. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bulletin of Experimental Biology and Medicine, 2003. pubmed.ncbi.nlm.nih.gov
2. "Peptide promotes overcoming of the division limit in human somatic cells." PubMed. pubmed.ncbi.nlm.nih.gov
3. Stone W. "FDA panel supports broadening access to peptides popular on the gray market." NPR, July 23–24, 2026. npr.org
This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.